Role of type i interferons in the activation of autoreactive B cells

Immunology and Cell Biology

Volumn 90, Issue 5, 2012, Pages 498-504

  Kiefer, Kerstin ^a   Oropallo, Michael A ^b   Cancro, Michael P ^b   Marshak Rothstein, Ann ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

autoimmunity; B cell; SLE; type I IFN

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AUTOANTIGEN; BETA INTERFERON; DNA BINDING PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; RNA BINDING PROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8;

ACCESSORY CELL; ANTIGEN PRESENTATION; APOPTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL STIMULATION; CELL SURFACE; CELL SURVIVAL; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; DNA VIRUS; EXPERIMENTAL MODEL; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; KIDNEY DISEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RNA VIRUS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS INFECTION; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; IMMUNITY, INNATE; INTERFERON TYPE I; LYMPHOCYTE ACTIVATION; VIRUS DISEASES;

EID: 84861665596     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2012.10     Document Type: Review

References (106)

1. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
2. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225-234.
3. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-829.
4. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-530.
5. Braun D, Caramalho I, Demengeot J. IFN-αlpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002; 14: 411-419.
6. Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection. J Immunol 2006; 176: 4343-4351.
7. Fink K, Lang KS, Manjarrez-Orduno N, Junt T, Senn BM, Holdener M et al. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 2006; 36: 2094-2105.
8. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 2010; 207: 1485-1500.
9. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70: 562-569.
10. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum 1982; 25: 401-406.
11. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-1916.
12. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
13. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
14. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
15. Finke D, Eloranta ML, Ronnblom L. Endogenous type I interferon inducers in autoimmune diseases. Autoimmunity 2009; 42: 349-352.
16. Cavlar T, Ablasser A, Hornung V. Induction of type I Ifns by intracellular DNA sensing pathways. Immunol Cell Biol 2012; 90: 474-482.
17. Choubey D, Panchanathan R, Duan X, Liu H, Liu H. Emerging roles for the interferoninducible p200-family proteins in sex bias in systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31: 893-906.
18. Schattgen SA, Fitzgerald KA. The PYHIN protein family as mediators of host defenses. Immunol Rev 2011; 243: 109-118.
19. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ et al. RNAassociated autoantigens activate B cells by combined B cell antigen receptor/ Toll-like receptor 7 engagement. J Exp Med 2005; 202: 1171-1177.
20. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416: 603-607.
21. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004; 199: 1631-1640.
22. Bave U, Magnusson M, Eloranta ML, Perers A, Alm GV, Ronnblom L. Fc gamma RIIa is expressed on natural IFN-αlpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-αlpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171: 3296-3302.
23. Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449: 564-569.
24. Ronnblom L, Eloranta ML, Alm GV. Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity. Autoimmunity 2003; 36: 463-472.
25. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002; 32: 163-173.
26. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178-183.
27. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
28. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992; 65: 70-74.
29. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998; 91: 393-399.
30. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511-518.
31. Adam C, Thoua Y, Ronco P, Verroust P, Tovey M, Morel-Maroger L. The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice. Clin Exp Immunol 1980; 40: 373-382.
32. Heremans H, Billiau A, Colombatti A, Hilgers J, de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease. Infect Immun 1978; 21: 925-930.
33. Mathian A, Gallegos M, Pascual V, Banchereau J, Koutouzov S. Interferon-alpha induces unabated production of short-lived plasma cells in pre-autoimmune lupusprone (NZB-NZW)F1 mice but not in BALB/c mice. Eur J Immunol 2011; 41: 863-872.
34. Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A. IFN-αlpha confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol 2011; 187: 1506-1513.
35. Niewold TB, Kelly JA, Kariuki SN, Franek BS, Kumar AA, Kaufman KM et al. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis 2012; 71: 463-469.
36. Paun A, Reinert JT, Jiang Z, Medin C, Balkhi MY, Fitzgerald KA et al. Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response. J Biol Chem 2008; 283: 14295-14308.
37. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 2005; 280: 17005-17012.
38. Yanai H, Chen HM, Inuzuka T, Kondo S, Mak TW, Takaoka A et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc Natl Acad Sci USA 2007; 104: 3402-3407.
39. Kariuki SN, Franek BS, Kumar AA, Arrington J, Mikolaitis RA, Utset TO et al. Traitstratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther 2010; 12: R151.
40. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci USA 2010; 107: 10154-10159.
41. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T et al. Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 2005; 434: 243-249.
42. Richez C, Yasuda K, Bonegio RG, Watkins AA, Aprahamian T, Busto P et al. IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/-mouse models of systemic lupus erythematosus. J Immunol 2010; 184: 796-806.
43. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005; 76: 528-537.
44. Karaghiosoff M, Neubauer H, Lassnig C, Kovarik P, Schindler H, Pircher H et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000; 13: 549-560.
45. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci USA 2003; 100: 11594-11599.
46. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-αlpha in lupus patients in vivo. J Immunol 2009; 182: 34-38.
47. Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007; 39: 1065-1067.
48. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134: 587-598.
49. Rozzo SJ, Allard JD, Choubey D, Vyse TJ, Izui S, Peltz G et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001; 15: 435-443.
50. Panchanathan R, Shen H, Duan X, Rathinam VA, Erickson LD, Fitzgerald KA et al. Aim2 deficiency in mice suppresses the expression of the inhibitory Fcgamma receptor (FcgammaRIIB) through the induction of the IFN-inducible p202, a lupus susceptibility protein. J Immunol 2011; 186: 6762-6770.
51. Panchanathan R, Liu H, Liu H, Fang CM, Erickson LD, Pitha PM et al. Distinct regulation of murine lupus susceptibility genes by the IRF5/Blimp-1 axis. J Immunol 2012; 188: 270-278.
52. Pramanik R, Jorgensen TN, Xin H, Kotzin BL, Choubey D. Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004; 279: 16121-16127.
53. Lee PY, Kumagai Y, Li Y, Takeuchi O, Yoshida H, Weinstein J et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med 2008; 205: 2995-3006.
54. Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 2006; 168: 1227-1240.
55. Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007; 56: 3770-3783.
56. Santiago-Raber ML, Kikuchi S, Borel P, Uematsu S, Akira S, Kotzin BL et al. Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol 2008; 181: 1556-1562.
57. Waters ST, Fu SM, Gaskin F, Deshmukh US, Sung SS, Kannapell CC et al. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol 2001; 100: 372-383.
58. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183: 6021-6029.
59. Jorgensen TN, Roper E, Thurman JM, Marrack P, Kotzin BL. Type I interferon signaling is involved in the spontaneous development of lupus-like disease in B6.Nba2 and (B6.Nba2-NZW)F(1) mice. Genes Immun 2007; 8: 653-662.
60. Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibodymediated glomerulonephritis. J Immunol 2009; 183: 6831-6838.
61. Hron JD, Peng SL. Type I IFN protects against murine lupus. J Immunol 2004; 173: 2134-2142.
62. Schwarting A, Paul K, Tschirner S, Menke J, Hansen T, Brenner W et al. Interferonbeta: a therapeutic for autoimmune lupus in MRL-Faslpr mice. J Am Soc Nephrol 2005; 16: 3264-3272.
63. Braun D, Geraldes P, Demengeot J. Type I interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 2003; 20: 15-25.
64. Hondowicz BD, Alexander ST, Quinn III WJ, Pagan AJ, Metzgar MH, Cancro MP et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int Immunol 2007; 19: 465-475.
65. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
66. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-798.
67. Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov 2011; 10: 335-336.
68. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994; 371: 389-395.
69. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999; 190: 1697-1710.
70. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000; 404: 995-999.
71. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
72. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003; 62: 168-171.
73. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
74. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.
75. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ et al. BAFF and MyD88 signals promote a lupus-like disease independent of T cells. J ExpMed 2007; 204: 1959-1971.
76. Khare SD, Sarosi I, Xia XZ, McCabe S, Miner K, Solovyev I et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3370-3375.
77. Wolf AI, Mozdzanowska K, Quinn III WJ, Metzgar M, Williams KL, Caton AJ et al. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Invest 2011; 121: 3954-3964.
78. Gandhi KS, McKay FC, Schibeci SD, Arthur JW, Heard RN, Stewart GJ et al. BAFF is a biological response marker to IFN-βeta treatment in multiple sclerosis. J Interferon Cytokine Res 2008; 28: 529-539.
79. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kumpfel T, Pellkofer H et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008; 131: 1455-1463.
80. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005; 204: 27-42.
81. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-249.
82. Blanco P, Pitard V, Viallard JF, Taupin JL, Pellegrin JL, Moreau JF. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 201-211.
83. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-αlpha in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
84. Green NM, Laws A, Kiefer K, Busconi L, Kim YM, Brinkmann MM et al. Murine B cell response to TLR7 ligands depends on an IFN-βeta feedback loop. J Immunol 2009; 183: 1569-1576.
85. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S et al. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005; 174: 4043-4050.
86. Uccellini MB, Busconi L, Green NM, Busto P, Christensen SR, Shlomchik MJ et al. Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-αlpha. J Immunol 2008; 181: 5875-5884.
87. Bayer W, Lietz R, Ontikatze T, Johrden L, Tenbusch M, Nabi G et al. Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 2011; 8: 75.
88. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006; 440: 540-544.
89. Badr G, Saad H, Waly H, Hassan K, Abdel-Tawab H, Alhazza IM et al. Type I interferon (IFN-αlpha/beta) rescues B-lymphocytes from apoptosis via PI3Kdelta/Akt, Rho-A, NFkappaB and Bcl-2/Bcl(XL). Cell Immunol 2010; 263: 31-40.
90. Mitani Y, Takaoka A, Kim SH, Kato Y, Yokochi T, Tanaka N et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 2001; 6: 631-640.
91. Douagi I, Gujer C, Sundling C, Adams WC, Smed-Sorensen A, Seder RA et al. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J Immunol 2009; 182: 1991-2001.
92. Oganesyan G, Saha SK, Pietras EM, Guo B, Miyahira AK, Zarnegar B et al. IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production. J Biol Chem 2008; 283: 802-808.
93. Peng SL, Szabo SJ, Glimcher LH. T-bet regulates IgG class switching and pathogenic autoantibody production. Proc Natl Acad Sci USA 2002; 99: 5545-5550.
94. Gerth AJ, Lin L, Peng SL. T-bet regulates T-independent IgG2a class switching. Int Immunol 2003; 15: 937-944.
95. de Goer de Herve MG, Durali D, Dembele B, Giuliani M, Tran TA, Azzarone B et al. Interferon-alpha triggers B cell effector 1 (Be1) commitment. PLoS One 2011; 6: e19366.
96. Liu N, Ohnishi N, Ni L, Akira S, Bacon KB. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat Immunol 2003; 4: 687-693.
97. Busconi L, Bauer JW, Tumang JR, Laws A, Perkins-Mesires K, Tabor AS et al. Functional outcome of B cell activation by chromatin immune complex engagement of the B cell receptor and TLR9. J Immunol 2007; 179: 7397-7405.
98. Jarousse N, Trujillo DL, Wilcox-Adelman S, Coscoy L. Virally-induced upregulation of heparan sulfate on B cells via the action of type I IFN. J Immunol 2011; 187: 5540-5547.
99. Evans SS, Collea RP, Appenheimer MM, Gollnick SO. Interferon-alpha induces the expression of the L-selectin homing receptor in human B lymphoid cells. J Cell Biol 1993; 123: 1889-1898.
100. Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 1997; 27: 2366-2374.
101. Wang JH, Li J, Wu Q, Yang P, Pawar RD, Xie S et al. Marginal zone precursor B cells as cellular agents for type I IFN-promoted antigen transport in autoimmunity. J Immunol 2010; 184: 442-451.
102. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010; 10: 236-247.
103. Engel P, Gomez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011; 63: 127-156.
104. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-2589.
105. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
106. Goenka R, Barnett LG, Silver JS, O'Neill PJ, Hunter CA, Cancro MP et al. Cutting edge: dendritic cell-restricted antigen presentation initiates the follicular helper T cell program but cannot complete ultimate effector differentiation. J Immunol 2011; 187: 1091-1095.